尼达尼布对进展性肺纤维化患者症状的影响
INBUILD试验纳入663例进展性肺纤维化患者,随机给予尼达尼布或安慰剂,用L-PF问卷评估52周症状变化。结果显示尼达尼布组呼吸困难、疲劳、咳嗽及疾病影响评分的恶化程度均显著小于安慰剂组。
要点
- 尼达尼布可减缓进展性肺纤维化患者52周内呼吸困难与疲劳的恶化。
- 尼达尼布组咳嗽评分下降而安慰剂组升高,提示咳嗽症状改善。
- 不同HRCT纤维化模式患者中观察到的症状获益趋势相似。
核心结论
- 基于L-PF问卷评分变化,尼达尼布在52周内减轻了进展性肺纤维化患者呼吸困难、疲劳和咳嗽的恶化及ILD对生活的影响。
研究设计与样本
- INBUILD试验为随机对照试验,患者按1:1随机接受尼达尼布或安慰剂治疗。
- 共663例患者接受治疗,纳入标准为HRCT上>10%范围的纤维化ILD(非IPF)且24个月内符合ILD进展标准。
- 采用重复测量混合模型评估L-PF问卷评分从基线至第52周的变化。
主要发现
- 第52周时,尼达尼布组L-PF总分校正均值增加0.5,安慰剂组增加5.1。
- 症状评分校正均值增加1.3 vs 5.3,呼吸困难评分增加4.3 vs 7.8,疲劳评分增加0.7 vs 4.0。
- 咳嗽评分在尼达尼布组下降1.8,安慰剂组增加4.3;影响评分尼达尼布组下降0.2,安慰剂组增加4.6。
- 在HRCT表现为UIP样纤维化模式及其他纤维化模式的患者中观察到相似结果。
临床怎么用
- 对于进展性肺纤维化患者,尼达尼布治疗可能有助于延缓呼吸困难、疲劳和咳嗽等症状的恶化。
- 临床评估中可结合L-PF问卷跟踪患者症状及疾病影响的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dyspnoea and cough can have a profound impact on the lives of patients with pulmonary fibrosis. We investigated the effects of nintedanib on the symptoms and impact of pulmonary fibrosis in patients with progressive pulmonary fibrosis (PPF) in the INBUILD trial using the Living with Pulmonary Fibrosis (L-PF) questionnaire. METHODS: Patients had a fibrosing interstitial lung disease (ILD) (other than idiopathic pulmonary fibrosis) of >10% extent on high-resolution computed tomography (HRCT) and met criteria for ILD progression within the prior 24 months. Patients were randomised 1:1 to receive nintedanib or placebo. Changes in L-PF questionnaire scores from baseline to week 52 were assessed using mixed models for repeated measures. RESULTS: In total, 663 patients were treated. Compared with placebo, there were significantly smaller increases (worsenings) in adjusted mean L-PF questionnaire total (0.5 versus 5.1), symptoms (1.3 versus 5.3), dyspnoea (4.3 versus 7.8) and fatigue (0.7 versus 4.0) scores in the nintedanib group at week 52. L-PF questionnaire cough score decreased in the nintedanib group and increased in the placebo group (-1.8 versus 4.3). L-PF questionnaire impacts score decreased slightly in the nintedanib group and increased in the placebo group (-0.2 versus 4.6). Similar findings were observed in patients with a usual interstitial pneumonia-like fibrotic pattern on HRCT and in patients with other fibrotic patterns on HRCT. CONCLUSION: Based on changes in L-PF questionnaire scores, nintedanib reduced worsening of dyspnoea, fatigue and cough and the impacts of ILD over 52 weeks in patients with PPF.
引用
- Wijsenbeek M, Swigris JJ, Inoue Y, et al. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. Eur Respir J. 2024. PMID: 38135442. doi:10.1183/13993003.00752-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。